Lilly Acquires Engage Bio for Up to $202 Million to Build Non-Viral DNA Delivery Platform
Eli Lilly acquired Engage Bio and its Tethosome non-viral DNA delivery platform for up to $202 million, aiming to overcome the immune and redosing limits of viral gene therapies.
5 min read4 sources